Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review

• Published in: Neurology Vol. 79; no. 11; p. 1130
• Main Authors: Lu, Ellen, Wang, Bing Wei, Guimond, Colleen, Synnes, Anne, Sadovnick, Dessa, Tremlett, Helen
• Format: Journal Article
• Language: English
• Published: United States 11.09.2012
• Subjects: Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Female; Glatiramer Acetate; Humans; Immunologic Factors - adverse effects; Immunologic Factors - therapeutic use; Interferon-beta - adverse effects; Interferon-beta - therapeutic use; Multiple Sclerosis - drug therapy; Natalizumab; Peptides - adverse effects; Peptides - therapeutic use; Pregnancy; Pregnancy Complications - drug therapy

To systematically review the literature regarding safety of disease-modifying drug (DMD) use during pregnancy on perinatal and developmental outcomes in offspring of patients with multiple sclerosis (MS). A PubMed and EMBASE search up to February 2012 was conducted with a manual search of references...